文献速递骨软组织肉瘤与黑色素瘤

帕博利珠单抗对比安慰剂作为已切除IIB或IIC期黑色素瘤辅助治疗:III期KEYNOTE-716研究无远处转移生存最终分析

Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.
PubMed 文献 · J Clin Oncol · 2024-03-07

KEYNOTE-716研究最终分析显示,在已切除IIB或IIC期黑色素瘤患者中,帕博利珠单抗组36个月无远处转移生存率为84.4%,安慰剂组为74.7%(HR 0.59,95%CI 0.44-0.79),无复发生存率分别为76.2%和63.4%(HR 0.62,95%CI 0.49-0.79),结果支持帕博利珠单抗辅助治疗。

要点

  • 帕博利珠单抗组36个月无远处转移生存率84.4%,安慰剂组74.7%(HR 0.59)。
  • 帕博利珠单抗组36个月无复发生存率76.2%,安慰剂组63.4%(HR 0.62)。
  • 安全性可控,与既往报告一致,结果支持帕博利珠单抗辅助治疗。

核心结论

  • 在已切除IIB或IIC期黑色素瘤患者中,帕博利珠单抗辅助治疗对比安慰剂显著改善无远处转移生存和无复发生存,结果继续支持帕博利珠单抗辅助治疗。

研究设计与样本

  • 随机、双盲、III期KEYNOTE-716研究(ClinicalTrials.gov标识符:NCT03553836),共976例患者随机分配至帕博利珠单抗组(n=487)或安慰剂组(n=489)。

主要发现

  • 截至2023年1月4日,中位随访39.4个月(范围26.0-51.4个月)。
  • 两组中位无远处转移生存均未达到,估计36个月无远处转移生存率帕博利珠单抗组84.4% vs 安慰剂组74.7%(HR 0.59,95%CI 0.44-0.79)。
  • 两组中位无复发生存均未达到,估计36个月无复发生存率帕博利珠单抗组76.2% vs 安慰剂组63.4%(HR 0.62,95%CI 0.49-0.79)。
  • 无远处转移生存和无复发生存结果在大多数预设亚组中一致,包括IIB期和IIC期黑色素瘤。
  • 帕博利珠单抗安全性可控,与既往报告一致。

关键数值与推荐

  • 36个月无远处转移生存率:帕博利珠单抗组84.4% vs 安慰剂组74.7%(HR 0.59,95%CI 0.44-0.79)。
  • 36个月无复发生存率:帕博利珠单抗组76.2% vs 安慰剂组63.4%(HR 0.62,95%CI 0.49-0.79)。

临床怎么用

  • 这些结果继续支持帕博利珠单抗辅助治疗用于已切除IIB或IIC期黑色素瘤患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Pembrolizumab adjuvant therapy was shown to significantly improve recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in patients with resected stage IIB or IIC melanoma in earlier analyses of the randomized, double-blind, phase III KEYNOTE-716 study (ClinicalTrials.gov identifier: NCT03553836). We report results of the protocol-specified final analysis of DMFS for KEYNOTE-716. Overall, 976 patients were randomly allocated to pembrolizumab (n = 487) or placebo (n = 489). As of January 4, 2023, median follow-up was 39.4 months (range, 26.0-51.4 months). The median DMFS was not reached in either treatment group, and the estimated 36-month DMFS was 84.4% for pembrolizumab and 74.7% for placebo (hazard ratio [HR], 0.59 [95% CI, 0.44 to 0.79]). The median RFS was not reached in either treatment group, and the estimated 36-month RFS was 76.2% for pembrolizumab and 63.4% for placebo (HR, 0.62 [95% CI, 0.49 to 0.79]). DMFS and RFS results were consistent across most prespecified subgroups, including stage IIB and stage IIC melanoma. The safety profile of pembrolizumab was manageable and consistent with previous reports. These results continue to support the use of pembrolizumab adjuvant therapy in patients with resected stage IIB or IIC melanoma.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Luke JJ, Ascierto PA, Khattak MA, et al. Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. J Clin Oncol. 2024. PMID: 38452313. doi:10.1200/JCO.23.02355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。